

Index

Page numbers followed by an f denote a figure on the corresponding page.

A

- A1, NOXA neutralization of, 203
- ABC1, 160
- ABC7, 160
- ABT-737, 226, 226f
- Accidental cell death, 121
- Acinus, 21
- Actin cytoskeleton, 162, 165f
- Actin polymerization, 22
- Active cell death, 1, 4–5
- Active site, caspase, 11
- Acute lymphoproliferative syndrome (ALPS), 95, 129
- Acute myelogenous leukemia, 211
- Acylation step of caspase cleavage, 12, 12f
- Adapter proteins, 5–6, 32–33, 34f
- Adaptive immune response, consequences of dying cells for, 169–170
- Adenosine nucleotide transporter (ANT), 55, 56f
- Adenosine triphosphatase type 11C (ATP11C), 22, 23f
- AFR-BP1, 200
- AIF (apoptosis-inducing factor), 54–55, 54f
- AIM2, 113, 113f
- AKT, 76–77, 79, 79f, 142, 196, 208
- Alcoholic cirrhosis, 228
- ALPS (acute lymphoproliferative syndrome), 95
- Aminophospholipid translocase, 151
- Amphibian metamorphosis, 186, 186f
- AMPK, 140, 142
- Amylotrophic lateral sclerosis (ALS), 132
- Annexin V, detecting phosphatidylserine by use of, 152–153, 152f–153f
- Anoctamin-6, 154
- Anoikis, 198
 - BIM and BMF mediation of, 78
 - pathway of, 78f
- Antagonistic pleiotropy, 196, 196f
- Anthracyclines, 216
- Anthrax, 112
- Anti-apoptotic BCL-2 proteins
 - BH3 profiling and, 226–227
 - cell proliferation and, 196–198
 - controlled by signaling, 79–80, 79f
 - inactivation by NOXA, 203
 - inactivation by PUMA, 203
 - inhibition for cancer therapy, 226–227
 - models of BH3-only protein function in apoptosis, 71–73, 73f
 - MOMP prevention by, 64–68, 66f–67f
 - p53 sequestered by, 204–205, 205f
- Antibody diversity, 198
- Antigen presentation, 169–170
- AP-1, 97
- APAF1 (apoptotic protease activating factor-1), 208, 213
 - caspase-9 activation, 47–48, 48f–49f
 - CICD and, 52–53, 53f
 - cytochrome c and, 48, 58–59, 146
 - domains of, 47–48, 48f
 - effect of deletion in, 49, 50f, 99, 192
 - homologs, 56–59, 57f, 180, 182

- APAF1 (apoptotic protease activating factor-1)
(Continued)
in neuron selection, 187
NLRs (Nod-like receptors) and, 115–116, 115f
vertebrate limb development and, 185
- APAF1-related killer (ARK), 56–57, 57f–58f, 59,
182, 183f
- APAFs (apoptotic protease activating factors),
56–59, 57f, 80
- APO-1, 89, 90f
- APO-2L, 90, 90f
- Apoptosis, 1
as an Achilles' heel of cancer, 209
bottom-up view of, 5–6
caspases involved in (see Caspase(s))
compensatory proliferation induced by, 176
connections to cell cycle, 195–197
cytotoxic lymphocyte induction of, 29–31,
29f–30f
death receptor pathway, 89–102
in *Drosophila* metamorphosis, 182–183, 183f
evolution of, 116
features of, 2, 3f
“find-me” signals, 150–151, 151f
HMGB1 oxidation in, 170, 171f
importance in mammalian development,
192–193
inducers of, 8, 10
inhibition of inflammation, 168–169, 168f
in nematode development, 180–181, 181f
in neuron selection, 187–188
p53 and, 200, 202–208, 203f, 207f
pathways, 5–10, 33f (see also *specific pathways*)
as cancer cause, 212–214, 213f
cross-talk, 10
death-receptor, 6, 8, 8f
inflammasome, 8, 9f, 10
mitochondrial, 6, 7f
sublethal engagement, 213, 213f
phosphatidylserine externalization, 151–153
proliferation and, 195–198
removal of apoptotic cells, 10
selection in development and, 187–191
“stay-away” signals, 155
TRAIL and, 95–96
in vertebrates development, 184–187,
185f–186f
- Apoptosis-inducing factor (AIF), 54–55, 54f
- Apoptosomes, 48–49, 48f, 56–59, 57f–58f, 105
- Apoptotic bodies, 2
- Apoptotic protease activating factors (APAFs),
56–59, 57f, 80. See also APAF1
(apoptotic protease activating factor-1)
- APP, 90, 90f, 214
- ARF, 199–200, 199f, 227
- ARK (APAF1-related killer), 56–57, 57f–58f, 59,
182, 183f
- ASC, 106–107, 106f–107f
NLRC4 binding, 112
NLRP2 and, 113
NLRP3 binding, 109, 110f, 111
- ASNT (adenosine nucleotide transporter), 55, 56f
- ATG5, 183
- ATG7, 141, 183
- ATG13, 140, 142
- Atherosclerosis, 114
- ATM, 200, 207
- ATP11C (adenosine triphosphatase type 11C),
22, 23f
- ATR, 200
- Autoimmune diseases, 174, 195
- Autoimmunity, 1
- Autophagic cell death, 169
cancer and, 214
in *Drosophila*, 183–184, 183f
features of, 2–3, 3f
- Autophagolysosomes, 139, 139f, 143, 143f
- Autophagosomes, 139, 139f, 141, 142f, 145f,
146, 183f
- Autophagy, 2, 137–147
cancer and, 214
canonical, 171, 173
in *Drosophila*, 164, 183–184, 184f
mammalian, 140–141, 141f–142f
mitochondria, removal of, 87–88, 87f–88f
mitophagy, 143–144, 144f–145f, 146
pathway, 139–143
engagement of, 139–143
hierarchical action, 139, 140f
as survival mechanism, 138–139
- Autopods, 184, 185f
- B**
- Bacterial sepsis, treated with caspase inhibitors,
228
- Bacterial toxins, 83–84, 84f, 112
- Baculovirus, 39, 41, 43–44
- Baculovirus IPA repeat (BIR), 41–42, 43f
- BAD, 73f, 211

- as growth factor signaling sensor, 77, 77f
 - in neuron selection, 187
 - role in regulating glucose metabolism in mammals, 85
- BAI1**, 157, 158f, 162, 164f
- BAK**, 99, 100f, 221–222
- activation, 66f, 68–72, 72f
 - anti-apoptotic proteins action on, 64–66, 66f
 - BH domain organization, 62f
 - calcium homeostasis and, 85
 - cancer therapy drugs to activate, 227
 - effect of deletion of, 192
 - as effector of MOMP, 62–64
 - inhibition, 66f
 - mitochondrial dynamics and, 86
 - in neuron selection, 187
 - nonapoptotic cell death in intestines lacking, 147, 148f
 - pharmacological inhibition of activation, 229–230
 - PUMA activation of, 203
 - structure of, 65f
 - in vertebrate limb development, 185, 185f
- Basigin**, 23, 23f
- BAX**, 99, 100f, 221–222
- activation, 68–72, 69f–72f
 - anti-apoptotic proteins action on, 64–66
 - BH domain organization, 62f
 - calcium homeostasis and, 85
 - cancer therapy drugs to activate, 227
 - effect of deletion of, 192
 - as effector of MOMP, 62–64, 63f
 - mitochondrial dynamics and, 86
 - in neuron selection, 187
 - nonapoptotic cell death in intestines lacking, 147, 148f
 - as p53 target, 203–205, 205f
 - pharmacological inhibition of activation, 229–230
 - PUMA activation of, 203
 - structure of, 65f, 84f
 - structure of activated, 69f–70f
 - in vertebrate limb development, 185, 185f
- BCL-2**
- autophagy regulation, 142
 - BAD specificity for, 211
 - cell proliferation and, 197–198, 197f–198f
 - constitutive expression of, 198
 - in lymphocyte selection, 190, 191f
 - Venetoclax binding to, 226
- BCL-2 homology (BH) domains**, 61, 62f
- BCL-2 proteins**, 6, 7f, 61–88. *See also specific proteins*
- amphibian metamorphosis and, 186
 - antagonistic pleiotropy regulated by, 196
 - anti-apoptotic
 - BH3 profiling and, 226–227
 - cell proliferation and, 196–198
 - controlled by signaling, 79–80, 79f
 - inactivation by NOXA, 203
 - inactivation by PUMA, 203
 - inhibition for cancer therapy, 226–227
 - models of BH3-only protein function in apoptosis, 71–73, 73f
 - MOMP prevention by, 64–68, 66f–67f
 - p53 sequestered by, 204–205, 205f
 - bacterial toxin and, 83–84, 84f
 - BH domains, 61, 62f
 - BH3-only proteins
 - BAX and BAK activation, 68–72
 - MOMP and apoptosis promoted by, 66–73
 - as stress sensors, 74–79
 - BID as protease sensor, 75, 76f
 - BIM and BAD as growth factor signaling sensors, 75–77, 76f–77f
 - BIM and BMF as anoikis mediators, 78
 - BOK regulation, 73–74, 74f
 - mitochondrial pathway of apoptosis, 61–88
 - MOMP and, 220–222, 221f–222f
 - in nonhuman animals, 80–82, 81f–82f
 - roles in cells, 84–88
 - apoptosis, 61–84
 - calcium regulation, 85
 - mitochondrial dynamics, 85–86, 87f
 - removal of mitochondria, 87–88, 88f
 - viral, 82–83, 82f–83f
- BCL-xL**, 226
- Beclin-1**, 87–88, 88f, 140, 141f, 142–143, 214
- β1-GP1**, 155, 156f
- BH3 mimetics**, 209–210, 209f, 226, 226f
- BH3 profiling**, 210–212, 210f–211f, 226–227
- BH3-only proteins**, 226
- autophagy and, 142–143
 - BAX and BAK activation, 68–72
 - BH3 profiling, 210–212, 210f–211f
 - EGL1, 180–181, 181f
 - in lymphocyte selection, 189–191, 191f
 - mammalian breast development and, 186
 - MOMP and apoptosis promoted by, 66–73
 - in neuron selection, 187

- BH3-only proteins (*Continued*)
as stress sensors, 74–79
 BID as protease sensor, 75, 76f
 BIM and BAD as growth factor signaling sensors, 75–77, 76f–77f
 BIM and BMF as anoikis mediators, 78
vertebrate limb development and, 185
- BID, 99–100, 100f
activation by caspase-1, 114
BAX/BAK activation, 68–69, 71f
caspase-2 and, 116
as p53 target, 203
pathway for cleavage and activation of, 76f
as protease sensor, 75
structure of, 75f
- BIM, 101, 209
anoikis mediated by, 78
BAX/BAK activation, 68–69, 71f, 73f
as growth factor signaling sensor, 75–77
in lymphocyte selection, 189–191, 191f
mammalian breast development and, 186
in neuron selection, 187
in vertebrate limb development, 185, 185f
- “Bind-me” signals
bridging molecule recognition of, 155–156, 156f–157f
on dying cells, 151, 153
in other animals, 159–160, 161f
phagocyte receptors for, 157–159, 158f–159f
- BIR (baculovirus IPA repeat), 41–42, 43f
- Bistability in cell death pathways, 220–223
BCL-2 proteins and MOMP, 220–222, 221f–222f
caspase activation and inhibition, 222–223
in *Drosophila*, 224, 224f
in nematodes, 223, 223f
- Blebbing, plasma membrane, 2, 21–22, 22f
- BMF
anoikis mediated by, 78
mammalian breast development and, 186
in vertebrate limb development, 185, 185f
- BNIP3, 87, 88f, 144
- BOK, 208
effect if deketuif, 192
as effector of MOMP, 63
regulation of, 73–74, 74f
- Bone morphogenetic proteins (BMPs), 184–185
- BR-C, 182–183, 183f
- Bridging molecules
binding to dying cells, 155–156, 156f–157f
phagocyte receptors for, 157–159, 158f–159f
- Buffy, 81, 86
- Button experiment, 230–231, 231f
- C
- CAD (caspase-activated DNase), 20–21, 21f, 24, 166, 213–214, 214f
- Cadherins, 174
- Caenorhabditis elegans*
BCL-2 proteins, 80–81, 81f–82f
“bind-me” signals, 159–160, 161f
caspase activation, 56–57, 57f
caspases in, 14, 24–25, 25f, 36
cell death in development, 179–182, 180f–182f
developmental plan, 179–180, 180f
engulfment in, 162
mitochondrial fragmentation, 86
neurosecretory motor neuron (NMN) pathway of apoptosis in nematodes, 223, 223f
p53 protein, 207, 207f
- Calcineurin, 136
- Calcium
activation of NADPH oxidase, 133, 134f, 135f
lymphocyte selection and, 189, 191f
mitochondrial permeability transition (MPT) and, 135, 136f
- Calcium homeostasis, role of BCL-2 proteins in, 85
- Calcium pyrophosphate dihydrate (CPPD), 110
- Calpain, 134, 135f
- Calreticulin, 215–216
exposure on surface of dying cells, 151, 159, 170
immunogenic cell death and, 170
LRP1 interaction, 159–159
- Cancer, 1–2, 195–216
apoptosis as an Achilles’ heel of, 209–210
apoptotic pathways as cause of, 212–214, 213f
autophagic cell death and, 214
autophagy and, 214
BH3 profiling, 210–212, 210f–211f
collateral tissue damage during therapy, 212
defective p53 and, 201–202
drugs promoting cell death, 225, 226f, 227f, 228
eliminated by p53, 202
entosis, 215
ferroptosis and, 214–215
as gene therapy risk, 224–225
iatrogenic, 213–214
immunogenic cell death, 215–216

- model of BCL-2 protein interactions in
MOMP predicting outcome in patients,
222, 222f
- necroptosis and, 214
- “primed for death” status of, 210–212
- rarity, reasons for, 195
- therapies designed to trigger apoptosis, 174
- tumor suppressors, 198–199, 208
- Canonical autophagy, 171, 173
- CARD. *See* caspase-recruitment domains (CARDs)
- Cardiac glycosides, 216
- Caspase-1, 169, 228. *See also* Inflammatory caspases
- activation, 36–37
- by inflammasomes, 104–106, 105f
- by NLRs, 110–113, 110f
- by TLRs, 107
- ASC and, 106–107, 106f
- BID activation by, 114
- CARD domain, 107
- domain structure, 14f
- fibrils in inflammasomes, 107, 107f, 108f
- gasdermin D activation by, 114
- inhibition of, 43
- noncanonical secretion and, 114
- pyroptosis, 37, 38f
- Caspase-2, 228. *See also* Initiator caspases
- action on a tumor suppressor, 208
- activation of, 31, 38, 116–120, 117f, 119f
- CDK1 and, 147
- domain structure, 14f
- functions of, 38
- p53 activation by, 205–206, 206f
- Caspase-3, 13. *See also* Executioner caspases
- acinus cleavage by, 21
- activation of, 29
- blockage of XIAP inhibition of, 52f
- deficient mice, 25, 26f
- DNA fragmentation and, 20–21, 21f
- domain structure of, 14f
- inhibition of, 42, 43f
- mice deficient in, 49, 50f
- mutations in human cancers, 208
- in neuron selection, 187
- substrate preference, 15, 17, 17f
- Caspase-4. *See also* Inflammatory caspases
- adapterless activation of, 103–104
- caspase-1 activation, 37
- domain structure, 14f
- pyroptosis, 37
- Caspase-5. *See also* Inflammatory caspases
- adapterless activation of, 103–104
- caspase-1 activation, 37
- domain structure, 14f
- pyroptosis, 37
- Caspase-6, 13. *See also* Executioner caspases
- activation of, 29
- cleavage of lamins by, 21
- domain structure of, 14f
- substrate preference, 17f
- Caspase-7, 13. *See also* Executioner caspases
- acinus cleavage by, 21
- activation of, 27–29, 28f, 37
- blockage of XIAP inhibition of, 52f
- domain structure of, 14f
- structures of inactive and active, 27, 28f
- substrate preference, 15, 17, 17f
- Caspase-8. *See also* Initiator caspases
- activation of, 31, 35, 105
- death effector domain (DED), 92, 93f
- in death receptor pathway of apoptosis, 92–96,
94f, 98–102, 100f–101f
- deficiency and embryonic lethality, 192
- domain structure, 14f
- FLIP interaction with, 35
- inhibition of, 43
- MALT heterodimer with, 35
- mutations in human cancers, 208
- necroptosis inhibition by, 127–129,
128f
- RIPK1 cleaved by, 12/8f, 127–128
- Caspase-9, 182, 208, 213. *See also* Initiator caspases
- activation of, 31, 34, 35f, 105
- amphibian metamorphosis and, 186
- blockage of XIAP inhibition of, 52f
- deficient mice, 25
- domain structure, 14f
- effect of deletion in, 192
- IAP-binding sequence, 59, 60f
- inhibition of, 42
- mice deficient in, 49, 50f
- in mitochondrial pathway of apoptosis, 47–49,
47f, 49f
- in neuron selection, 187
- suicide switch in engineered T cells, 225f
- vertebrate limb development and, 185
- Caspase-10. *See also* Initiator caspases
- DISC, 93
- domain structure, 14f

- Caspase-11
 - adapterless activation of, 103–104
 - caspase-1 activation, 37
 - pyroptosis, 37
- Caspase-12, 37
- Caspase(s), 11–26. *See also specific caspases*
 - activation, 27–38
 - adapterless, 103–104
 - ASC and, 106–107, 106f
 - caspase-2, 38
 - death folds and, 32–33, 34f
 - death receptor pathway, 89
 - by dimerization, 34–35, 35f
 - by dimerization with other molecules, 35–36
 - in *Drosophila*, 57–58, 58f
 - executioner caspases, 27–29, 28f
 - by induced proximity, 103–104, 225
 - by inflammasomes, 104–106, 105f
 - inflammatory caspases, 36–37, 38f
 - initiator caspases, 31–32, 32f, 34
 - LPS, 104, 105f, 111
 - by mitochondria, 47–49, 47f–49f, 51
 - in nematodes, 56–57, 57f
 - in other animals, 36, 38–39, 39f
 - active site, 11
 - bistability in activation and inhibition, 222–223
 - caspase-12 and beyond, 38–39, 39f
 - CED3, 180–181, 181f–182f
 - cleavage sites, 11, 15–17, 15f, 18f, 19t
 - in *Drosophila* metamorphosis, 182, 183f–184f
 - executioner, 5–6, 6f, 8, 8f
 - inhibition, 39–43
 - cancer therapy and, 214
 - synthetic, 40–41, 40f–41f
 - viral, 39–43
 - initiator, 5–6, 6f, 8, 8f
 - as killers, 24–26, 25f–26f
 - LPC production and, 150, 151f
 - mechanism of action, 11–13, 12f
 - mitochondrial effects of executioner caspases, 23–24
 - in nematodes, 180–181, 181f–182f
 - in neuron selection, 187
 - nuclear events mediated by, 20–21, 21f
 - in other animals, 14, 15f
 - PGE₂ production and, 176
 - pharmacologic inhibition, 228, 229f
 - plasma membrane events caused by, 21–22, 22f–23f
 - prodomain structure, 13, 14f
 - substrate for executioner caspases, 18, 20
 - substrate preferences, 15–17, 17f–18f, 19t
 - types of, 13
- Caspase-activated DNase (CAD), 20–21, 21f, 24, 166, 213–214, 214f
- Caspase-independent cell death (CICD), 52–55, 53f–54f
- Caspase-recruitment domains (CARDs), 33, 47–48, 47f–49f, 56, 57f, 91, 91f
 - of ASC, 106–107, 106f–107f
 - of caspase-2, 116–117
 - LPS binding to, 104
 - of NLR4, 112
- Cavitation, 185–186, 186f
- C3b, 156, 157f, 158
- CD31, 154, 154f
- CD36, 158, 160, 183
- CD47, 154, 154f
- CD68, 158
- CD91, 158
- CD95, 89, 90f, 228
 - apoptosis triggered by, 91–95, 94f
 - death domain (DD), 92f
 - defects and acute lymphoproliferative disease, 129
 - defects in signaling, 95, 96f
 - FADD and, 92–93, 92f, 95–96
 - ischemia-reperfusion injury and, 136
 - p53 induction of expression of, 203
- CDC50A, 22, 23f
- CDK1 (cyclin-dependent kinase 1), 147
- CD95-L, 90, 90f, 91, 95, 98, 129
- CED1, 159, 161f, 162, 163f, 184
- CED2, 162
- CED3, 14, 15f, 25, 25f, 36, 56–57, 57f, 164, 180–181, 181f–182f
- CED4, 56–57, 57f, 80–81, 81f–82f, 86, 180–181, 181f–182f
- CED5, 162
- CED6, 162, 163f
- CED7, 163f
- CED8, 151
- CED9, 57, 80–81, 81f–82f, 86
- CED10, 162, 163f
- CED12, 162
- Cell cycle, 118–120, 119f, 195
- Cell death. *See also Apoptosis; Necroptosis*
 - accidental, 121
 - active, 1, 4–5

- autophagic, 2–3, 3f, 169, 183–184, 183f, 214
 - bistability in pathways, 220–223
 - caspase-independent cell death (CICD), 52–55, 53f–54f
 - consequences, 149–177
 - definition of, 9
 - in development, 179–193
 - as essential, 1–2
 - immunogenic, 215–216
 - limiting, 228–230
 - nonapoptotic pathways, 121–148
 - reasons for, 1–2
 - types of, 2–4, 3f–4f
 - Cell death by design, 224–228
 - drugs promoting cell death, 225, 226f, 227f, 228
 - suicide switches, 224–225, 225f
 - Cell division and stochastic death, 218f
 - Cellular states, models of death and, 217–220
 - Centrosomes
 - aberrant, 205–206, 206f
 - caspase-2 activation, 119, 119f
 - PIDD localization to, 118–119, 118f
 - CEP-1, 207, 207f
 - CES1, 180–181, 181f
 - Chk1, 200
 - Chk2, 200
 - Chloroquine, 214
 - Cholesterol management, 166, 167f
 - Chromatin condensation, 21
 - Chromatin fragmentation. *See* DNA fragmentation
 - Chronic hepatitis, 228
 - Chronic lymphoblastic leukemia, 17p-deleted, 226
 - CIAPs, 96–97, 227
 - CICD (caspase-independent cell death), 52–55, 53f–54f
 - Cisplatin, 215
 - c-Jun amino-terminal kinase (JNK), 77, 97
 - Clearance of dying cells
 - “bind-me” signals, 151, 153
 - bridging molecules, binding of, 155–156, 156f–157f
 - in *C. elegans*, 159–160, 161f
 - “clear-me” process, 166
 - disease and, 173–174, 174f
 - “don’t-eat-me” signals, 153–155
 - in *Drosophila*, 160, 161f
 - “eat-me” signals, 160, 162, 163f–165f
 - engulfment promotion of cell death, 162, 164, 166
 - entosis, 174–175, 175f
 - “find-me” signals, 150–151, 151f
 - LC3-associated, 170–173, 172f–173f, 175, 175f
 - phagocyte receptors, role of, 157–159, 158f–159f
 - “tether and tickle” model, 156–157
 - waste management, 149–150, 166, 167f
 - “Clear-me” process, 166
 - Cleft palate, 192
 - c-Myc, 212, 215
 - Cnidaria, 36
 - Colicins, 83, 84f
 - Combinatorial peptide libraries, identifying caspase specificity with, 15–17
 - Compensatory proliferation, 176–177, 176f
 - Complement proteins, 156, 157f, 158
 - Cornification, 4
 - CPPD (calcium pyrophosphate dihydrate), 110
 - C1q, 156, 157f, 158
 - CRKII, 162
 - Croquemort, 160, 161f, 183–184
 - Cross talk, 10
 - Cross-priming, 216
 - Cyclin-dependent kinase 1 (CDK1), 147
 - Cyclophilin D, 55–56, 56f, 135–136, 229
 - Cyclosporin A, 136, 229
 - CYLD, 98, 98f, 128
 - Cysteine protease, 11
 - Cystine, 137, 138f, 204
 - Cystine/glutamate antiporter, 137, 138f
 - Cytochrome c, 6, 7f, 48–49, 49f, 61, 116, 192, 210
 - APAF1 activation, 48, 58–59, 146
 - MOMP and, 50–51, 50f
 - Cytokines. *See also specific molecules*
 - adaptive immune response and, 170
 - caspase-1 processing of precursors, 36–37
 - innate immune system and, 167–169
 - Cytokinesis, failure of, 119f, 120
 - Cytoskeleton
 - anoikis and, 78
 - rearrangement of the actin, 162, 165f
 - Cytotoxic lymphocytes, 29–31, 29f–30f, 216
- ## D
- DAI, 124, 125f
 - Damage-associated molecular patterns (DAMPs), 106
 - as “find-me” signals, 150–151
 - as maturation signals to dendritic cells, 170

- Damage-associated molecular patterns (DAMPs)
(Continued)
NLRs and, 109, 109f
oxaliplatin-induced production of, 215
release by dying cells, 150–151, 167
- Damm, 14, 15f
- Darwin, Charles, 231
- DBorg1, 81
- DBorg2, 81
- DCP1, 14, 15f, 36
- Deacylation step of caspase cleavage, 12, 12f
- Death, definition of, 9
- Death domain, 90–92, 91f–92f, 96, 98, 117
- Death effector domains (DEDs), 32–33, 91–94, 91f, 93f–94f, 102
- Death fold, 32–33, 34f, 109
- Death ligands, 89–91, 90f–91f
- Death receptor pathway of apoptosis, 6, 8, 8f, 89–102
CD95-induced pathway, 91–95, 94f
mitochondrial pathway engaged by, 99–101
in nonhuman animals, 102
sublethal engagement of, 213, 213f
TNFR1 and, 96–99
TRAIL and, 95–96
triggers of, 8, 10
- Death receptors, 6
necroptosis caused by, 123–124, 124f
in other animals, 102
p53 induction of expression of, 203
as subset of the tumor necrosis factor receptor family, 89–91, 90f–91f
- Death-inducing signaling complex (DISC), 93, 105, 128
- Death-receptor-mediated engagement of
necroptosis, 228
- DeBCL, 81, 86
- Decapentaplegic, 176
- Decay, 14, 15f
- Dendritic cells, 150, 168–170, 171f–172f
- Deubiquitinase (DUB), 128
- Development, cell death in, 1, 45, 179–193
bistability in cell death pathways, 223–224
in *Drosophila*, 182–184, 183f–184f, 224, 224f
importance in mammals, 192–193
in nematodes, 179–182, 180f–182f
selection, 187–191
lymphocytes, 188–191, 190f–191f
negative selection, 189–191, 190f–191f
neurons, 187–188, 188f
in vertebrates, 184–187, 185f–186f
- Developmental signals, mitochondrial pathway
and, 8
- DFADD, 102
- DFF45, 20. *See also* iCAD
- Diablo, 51
- DIAP1 (*Drosophila* IAP1), 41–43, 42f, 57, 58f, 59, 59f
- DIAP inhibitors, 182
- Digits in the vertebrate limb, development of,
184–185, 184f–185f
- Dimerization
activation of initiator caspases by, 34–35, 35f
initiator caspases can be activated by
dimerization with other molecules,
35–36
- Diphtheria toxin, 83, 84f
- Direct activator/derepressor model, 72–73, 73f,
221–222, 221f
- DISC (death-inducing signaling complex), 93,
105, 128
- Disease
cell death as component of, 1
clearance and, 173–174, 174f
inflammasomes in, 114–115
necroptosis and, 131–132, 132f
- DNA, cleavage of, 2
- DNA damage
apoptosis triggered by, 133
autophagy caused by, 143
p53 induction by, 200–201, 200f, 207, 207f
- DNA fragmentation, 18, 20–21, 21f, 54, 54f,
166
- DNA fragmentation factor of 40 kDa (DFF40), 20.
See also CAD
- DNA repair, 132
- DNase II, 166
- DNFA5, 122–123
- DOCK180, 162, 165f
- Domain structure of caspases, 13, 14f
- “Don’t-eat-me” signals on cells, 153–155
- DR3 (death receptor 3), 89, 90, 90f
- DR4 (death receptor 4), 89, 90f
- DR5 (death receptor 5), 89, 90f, 96, 203
- DR6 (death receptor 6), 89, 90, 90f, 214
- DRAM, 146
- Draper, 162, 164, 184
- Dredd, 36, 37, 102
- Drice, 14, 15f, 36, 182, 183f
- Dronc, 25f, 36, 41, 56–57, 58f, 59, 182, 183f

Drosophila

- ARK, 56–57, 57f–58f
- autophagy in, 164
- BCL-2 proteins, 81
- “bind-me” signals, 160, 161f
- caspase activation in, 57–58, 58f
- caspases in, 14, 15f, 25, 25f, 36, 37
- compensatory proliferation in, 176
- developmental apoptosis in, 224, 224f
- dFADD, 102
- DIAP1, 41–43, 42f, 57, 58f, 59, 59f
- Dredd, 102
- Dronc, 56–57, 58f, 59
- engulfment in, 162
- metamorphosis, 145, 182–184, 183f–184f
- mitochondrial fragmentation, 86
- p53-like protein, 206–207, 207f
- DUB (deubiquitinase), 128
- Dying cells. *See also* Clearance of dying cells
 - adaptive immune response and, 169–170
 - “bind-me” signals on, 151, 153
 - innate immune response induced by, 166–169
 - loss of “don’t-eat-me” signals, 154
 - as signals, 10
- Dynein motor complexes, 78

E

- E74, 182–183, 183f
- E93, 182–183, 183f
- “Eat-me” signals, 160, 162, 163f–165f
- Ecdysone, 182–183, 183f, 224
- Echinoderm, caspases in, 36
- EGL1, 81, 81f–82f, 86, 180–181, 181f, 207
- ELMO, 162, 165f
- Embryo implantation, 187
- Endopeptidases, 11, 30
- Endoplasmic reticulum-associated degradation (ERAD), 74, 74f
- Endosymbiosis, 45, 83
- Engulfment. *See also* Phagocytosis
 - cell death promoted by, 162, 164, 166
 - “eat-me” signals, 160, 162, 163f–165f
 - entosis, 174–175, 175f
- Entosis, 174–175, 175f, 187, 215
- Epithelial cells, entosis and, 174
- ERAD (endoplasmic reticulum-associated degradation), 74, 74f
- Erastin, 227
- ERK, 77

- E3-ubiquitin ligase, 42, 200
- Evolution, 231
- Excitotoxicity, 133, 134f
- Executioner caspases, 5–6, 6f, 8, 8f
 - activation of, 27–29, 28f
 - active sites of, 27
 - ATP11C cleavage by, 22
 - CED3 as, 164
 - Drice, 182, 183f
 - induce production of the “find-me” signal LPC, 151f
 - inhibition of, 42
 - key substrates for, 18, 20
 - as killer, 24–25
 - mitochondrial effects of, 23–24
 - pharmacologic inhibition of, 214
 - phospholipase A₂ activation by, 212
 - proforms of, 27–29, 28f
 - structure of, 13–14, 14f–15f

F

- FADD (FAS-associated death domain protein), 92–93, 92f–94f, 95–96, 98, 100f, 128–129, 128f
 - deficiency and embryonic lethality, 192
 - dFADD, 102
 - hypothetical connection between autophagy and necrosis, 146, 147f
 - RIPK1 binding, 129, 131
- Fas, 89, 90f
- Fas-L, 90, 90f, 229f
- FBW7, 79
- Ferroptosis, 137, 138f
 - cancer and, 214–215
 - ferrostatins, 229
 - induced pharmacologically, 227–228
 - p53 sensitizes cells for, 204, 214
- Ferrostatins, 229
- “Find-me” signals, 150–151, 151f
- FK506, 225
- FK-binding proteins (FKBPs), 225
- FLICE-like inhibitory protein (FLIP), 35, 93–95, 94f, 97, 99
 - deficiency and embryonic lethality, 192
 - FLIPs, 95
 - necroptosis inhibition by, 127–129, 128f
 - v-FLIP, 95
- Flippase, 22–23, 23f
- FOIP200, 140, 141f

Follicular lymphoma, 198
Form, created by death, 179
FOXO3a, 76, 76f

G

Gas6, 155, 156f, 157, 158f, 168
Gasdermin D, 104, 105f, 111, 114, 123
Gasdermin E, 122–123
Gelsolin, 22
Gene therapy, 224–225
Genetic engineering, introduction of suicide switches and, 224–225, 225f
Glutamate, neuron necrosis and, 133
Glutathione, 137, 138f, 204, 215
Glycogen synthase kinase, 79–80, 79f
Gout, 110, 110f, 114
GPX4, 137, 138f, 228
Graft rejection, 173
Granzyme B, 30–31, 30f, 43
Granzymes, 30–31, 30f
Grim, 59, 60f, 224
Growth factor signaling
 BIM and BAD as sensors for, 75–76, 76f–77f
 MVL-1 stability regulated by, 79–80, 79f
GULP, 162, 163f

H

Heart attacks, 134
Hermaphrodite-specific neurons (HSNs) cell death, 180–181, 181f
Herpes viruses v-FLIP, 95
Hid, 59, 60f, 182, 183f, 207, 224
High-mobility group protein B1 (HMGB1), 167, 170, 171f
HLH2, 180–181, 181f
HLH3, 180–181, 181f
Homeostasis, cell death essential to, 1
Homeostatic proliferation, 177
HRK, 187, 211
Human genome, 230
Hydroxyl radicals, 24

I

IAP-binding sequences, 59, 60f
IAPs
 caspase inhibited by, 223
 inhibition of, 51

 by caspase, 223
 in *Drosophila* apoptosis, 59, 59f
ICAD, 20, 21f, 24, 166, 213
Immune checkpoints, 216
Immune system development, 187, 188–191, 190f, 191f
Immunogenic cell death, 215–216
Induced proximity model, 31, 103–104
Infection, cell death induced by, 8, 9f, 10
Inflammasomes, 8, 9f, 10
 activation, 166, 169
 AIM2, 113, 113f
 ASC and, 106–107, 106f–107f
 caspase-1 activation by, 104–106, 105f
 in disease, 114–115
 general structures of, 107f
 NLRs (Nod-like receptors) and, 109–116
 disease and, 114–115
 NLRC4, 111–112, 112f
 NLRP1, 112–113, 113f
 NLRP2, 113
 NLRP3, 109–111, 110f, 114–115
 noncanonical, 104
 PAMP/DAMP triggering formation of, 106
 TLRs (Toll-like receptors) induction of, 107–108
 triggers of, 10
Inflammation
 cell death effect on, 169, 169f
 inhibition by apoptotic cells, 168–169, 168f
 necrosis and, 150
 response in apoptosis, 2
Inflammatory caspases
 function in secretion and cell death, 36–37
 structure of, 13, 14f
Inhibitor of apoptosis protein, 39, 41–44, 42f–44f
Initiator caspases, 5–6, 6f, 8, 8f
 activated by induced proximity, 225
 activation of, 31–32, 32f, 34
 by dimerization, 34–35, 35f
 by dimerization with other molecules, 35–36
 inactive form, 31
 structure of, 13–14, 14f–15f
Innate immune system, impact of dying cells on, 166–169
Inositol (1,4,5)-triphosphate (IP3), 85
Integrins, 157, 158f
Intein, 118
Interleukin-1, 36–37, 104, 114, 115, 169
Interleukin-18, 36–37, 104, 114, 115, 169

- Ischemia-reperfusion injury, 133–137, 135f–136f, 138f, 229
- J**
- JNK, 101, 189, 191f
Just So Stories (Kipling), 45
- K**
- Kaposi sarcoma virus vBCL-2, 83f
Kipling, Rudyard, 45
KRAS, 215
- L**
- Lactadherin, 155, 156f
Lactoferrin, 155
Lamins, 21
LC3, 141, 142f
LC3-associated phagocytosis and clearance, 170–173, 172f–173f
LE bodies, 173, 174f
Leukemia, 211–212
Leukotriene-B₄, 169
Li–Fraumeni syndrome, 201
Limb development, in vertebrates, 184–185, 184f–185f
Linker cell, 180, 180f
Lipid peroxidase, 228
Liver diseases, RIPK3 and, 131–132
LOX1, 158
LPS, caspase activation by, 104, 105f, 111
LRP1, 158, 162
LXR (liver X receptor), 166, 167f
Lymphoaccumulative disease, 95, 96f
Lymphocytes
 apoptosis and selection, 188–191, 190f–191f
 cytotoxic, 29–31, 29f–30f, 216
Lymphoma, 204, 226
Lysosomes, 139, 141, 146, 162, 165f, 166
- M**
- Macrophages, 150, 169, 171, 173, 177
 inflammatory response and, 169, 169f
 recruitment by “find-me” signals, 150, 151f, 155
 TGF- β production by, 168
 TIM4 deficient mice and, 157–158
 tingible body macrophage (TBM), 155, 155f
 in wound healing, 176
Major histocompatibility complex (MHC)
 molecules, 169
MALT, 35
Mammalian autophagy, 140–142, 141f–142f
Mammalian breast, 185–186
Mannose-binding lectin (MBL), 155–156, 156f
MAP kinases, 77
MCL-1, 66, 67f, 68, 77, 226
 mammalian breast development and, 186
 NOXA neutralization of, 211
 stability regulation by growth factor receptor signaling, 79–80, 79f
 TCTP binding to, 200
MDM2, 199–200, 204–205, 205, 206f, 223, 227
Mer, 157–158, 158f, 168, 168f
Metamorphosis, 179, 224
 amphibian, 186, 186f
 in *Drosophila*, 145, 182–184, 183f–184f
Metastasis, 214
MFGE8, 155, 156f, 157, 158f
MFN2, 144
MHC (major histocompatibility complex)
 molecules, 169
Michelangelo, 179
Milk fat globulin-E8, 155, 156f
“Minority MOMP,” 213, 213f
Mitochondria
 autophagy of, 143–144, 144f–145f, 146
 fragmentation of, 86
 functions of, 45
 necrosis, role in, 135
 NLRP3 inflammasome and, 111
 origins of, 45–47, 46f
 removal of, 87–88, 87f–88f
Mitochondrial dynamics, influenced by BCL-2 proteins, 85–86, 87f
Mitochondrial outer membrane permeabilization (MOMP), 6, 49–56, 60, 228
 BAX and BAK as effectors of, 62–64, 63f–64f, 68–72, 71f
 BH3 profiling and, 210f–211f
 bistability and, 220–222
 caspase-independent cell death (CICD), 52–55, 53f–54f
 cytochrome c release, 50–51, 50f
 death receptor signaling, 99–100, 100f–101f
 direct activator/derepressor model, 221–222, 221f
 minority, 213, 213f

- Mitochondrial outer membrane permeabilization (MOMP) (*Continued*)
- mitochondrial permeability transition, 55–56, 56f
 - in neuron selection, 187
 - neutralization model, 220–223, 221f
 - p53 and, 203, 205, 205f
 - pharmacological inhibition of activation, 229–230
 - prevention by anti-apoptotic BCL-2 proteins, 64–66, 66f–67f
 - promotion by BH3-only proteins, 66–73
 - BAX and BAK activation, 68–72
 - direct activator/derepressor model, 72–73, 73f
 - neutralization model, 72, 72f
 - protein release with, 51–52, 52f
- Mitochondrial pathway of apoptosis, 6, 7f, 45–60
- amphibian metamorphosis and, 186
 - apoptosomes in animals, 56–59, 57f–58f
 - BCL-2 protein family, 61–88
 - cancer therapy and, 211
 - caspase activation, 47–49, 47f–49f, 51
 - caspase-independent cell death (CICD), 52–55, 53f–54f
 - death receptor signaling engagement of, 99–101
 - disruption of mitochondrial outer membrane, 49–51
 - importance in mammalian development, 192
 - mitochondrial outer membrane
 - permeabilization (MOMP), 49–56, 50f, 52f, 60
 - mitochondrial permeability transition, 55–56, 56f
 - in neuron selection, 187–188
 - triggers of, 8
 - in vertebrate limb development, 185
- Mitochondrial permeability transition (MPT), 55–56, 56f, 135–136, 136f, 229
- Mitofusin-2, 86
- Mitophagy, 143–144, 144f–145f, 146
- Mitotic catastrophe, 147–148, 148f
- MLKL (mixed-lineage kinase domain-like protein), 125–127, 126f, 129, 132, 151
- development in deficient mice, 193
 - inhibition by necrosulfonamide, 229
- Models of death, cellular states and, 217–220
- MOMP. *See* Mitochondrial outer membrane permeabilization
- Morphological changes associated with apoptosis, 2, 3f
- Mouse double minute 2 (MDM2), 199–200, 204–205, 205, 206f, 223, 227
- MPT (mitochondrial permeability transition), 55–56, 56f, 135–136, 136f, 229
- MTOR, 140, 142, 143f
- MULE, 80, 200
- Mutations, cancer and, 195, 199, 201, 208, 213
- Myc, 195–197, 196f–197f, 201, 204, 208–209
- ## N
- NACHT domain, 48, 48f–49f, 115, 115f
- NAD⁺, 132–133
- NADPH, 137
- NADPH oxidase, 133–134, 134f135f
- NAIP, 112
- Natural killer cells, 29
- Navitoclax, 226
- NDUFS1, 24, 170
- Necroptosis, 123–137
- cancer and, 214
 - death receptors and, 123–124, 124f, 228
 - disease and, 131–132, 132f
 - importance in mammalian development, 192–193
 - inflammation induction, 169
 - inhibition by caspase-8 and FLIP, 127–129, 128f
 - ischemia-reperfusion injury, 136
 - MLKL and, 125–127, 126f
 - necrostatins, 228–229
 - pharmacologic induction of, 227
 - phosphatidylserine exposure, 151
 - priming T-cell responses, 170
 - as protective, 132
 - as recent evolutionary invention, 127
 - suicide switch engineering and, 225
 - TRIF and, 24, 125f
- Necrosis, 122f. *See also* Necroptosis
- autophagy in stressed cells is blocked, 143
 - cell death, 122–137
 - compensatory proliferation and, 176–177
 - DAMPs released by, 150–151, 167
 - excitotoxicity, 133, 134f
 - features of, 3–4, 4f
 - inflammation and, 150, 167
 - ischemia-reperfusion injury, 133–137, 135f–136f
 - linker cell death by, 180, 180f
 - mitochondria role in, 135
 - neuronal, 133

- PARP and, 132–133
PGE₂ production, 176–177
phosphatidylserine exposure, 151, 153
secondary, 122–123, 122f, 150
- Necrostatins, 123, 228–229
- Necrosulfonamide, 229
- Necrotic cells, removal of, 10
- Negative selection in self-nonsel self discrimination, 189–191, 190f–191f
- Negative-feedback regulation, 219–220
- Nematodes. *See also Caenorhabditis elegans*
BCL-2 proteins, 80–81, 81f–82f
caspase activation, 56–57, 57f
cell death in development, 179–182, 180f–182f
developmental plan, 179–180, 180f
lack of caspase-inhibitory IAP proteins, 43
p53 protein, 207, 207f
- NEMO, 97
- Nerve growth factor, 187
- Neural tube, closure of, 192
- Neuroblastoma, 208
- Neurons, selecting, 187–188, 188f
- Neuroplastin, 23, 23f
- Neurosecretory motor neuron (NMN) pathway of apoptosis in nematodes, 223, 223f
- Neurosecretory motor neuron (NMN) sister cell death, 180–181, 181f
- Neurotrophism model, 187
- Neutralization model, 72, 72f, 220–221, 221f
- Neutrophils, 150, 155, 169, 169f
- NF- κ B (nuclear factor- κ B), 97–99, 118, 128, 129, 170
- NHE-1, 80
- NIX, 87, 87f, 144
- NLRC4 inflammasome, 111–112, 112f
- NLRP1 inflammasome, 112–113, 113f
- NLRP3 inflammasome, 109–111, 110f, 114–115
- NLRs (Nod-like receptors), 109–116, 166
APAF1 and, 115–116, 115f
disease and, 114–115
NLRC4, 111–112, 112f
NLRP1, 112–113, 113f
NLRP2, 113
NLRP3, 109–111, 110f, 114–115
- Nonapoptotic cell death pathways, 121–148
accidental cell death, 121
autophagic cell death (type II cell death), 137–147
mitotic catastrophe, 147–148, 148f
necrosis (type III cell death), 122–137
- Noncanonical secretion, 114
- Nox, 133
- NOXA, 80
MCL-1 neutralization, 203, 211
as p53 target, 203
- Nuclear events mediated by caspase cleavage of specific substrates, 20–21, 21f
- Nuclear factor- κ B. *See* NF- κ B
- Nuclease, 20
- Nucleotide exchange factor, 162
- Nucleus changes in apoptosis, 2
- Nutlin-3, 227, 227f
- O**
- Omi, 51–52, 52f, 59, 60f, 99, 227
- On the Origin of Species* (Darwin), 231
- Oncogenes, 175, 195, 199, 201, 208–209, 212
- Oxaliplatin, 215
- P**
- p35, 43, 44
- p53, 119, 223
activation, 199–201, 199f–200f
by caspase-2, 205–206, 206f
by DNA damage, 200–202, 200f, 207, 207f
by ribosomal protein imbalance, 201
- apoptosis and, 200, 202–208, 203f, 207f
cytosolic p53, 204–205
in *Drosophila*, 206–207, 207f
in nematodes, 207, 207f
nuclear p53, 202–204
- ARF and, 199–200, 199f
- cancer and, 199, 201–202
- cytosolic, 204–205, 205f
- defective, 201–202
- gene mutation, 199
- induced apoptosis in other animals, 206–208, 207f
- MDM2 induction by, 199–201
- mitochondrial outer membrane permeabilization (MOMP) and, 203, 205, 205f
- nuclear, 202–204, 205f
- p53-MDM2 feedback loop, 199f
- regulation by ATM, 207
- stabilization of, 227
- targets of, 202–204, 202f
BAX, 203–205, 205f

- p53 (*Continued*)
 - BID, 203
 - death receptors, 203–204
 - ferroptosis, 204, 214
 - genes encoding pro-apoptotic proteins, 203, 203f
 - MDM2, 199
 - NOXA, 203
 - PUMA, 203, 205, 205f
- p21-activated kinase (PAK), 22
- Pancreatic islets, Myc in, 197, 197f
- Pancreatitis, RIPK3 and, 132
- Paracaspase, 35
- Parasite, 1
- Parkin, 144, 144f, 146
- PARP1 (poly(ADP-ribose) polymerase 1), 132–133
- Passive cell death, 4
- Pathogen-associated molecular patterns (PAMPs), 106, 116, 167, 170
 - LTRs and, 107–108, 108f
 - as maturation signals to dendritic cells, 170
 - NLR4 inflammasome and, 112
 - NLRs and, 109, 109f
- Pattern-recognition receptors (PRRs), 109, 166. *See also* NLRs (Nod-like receptors); TLRs
- Perforin, 30, 30f
- Peritonitis, 132
- Permeability transition pore (PTP), 55–56, 56f, 135
- Persister cells, 217–218
- PGE₂ (prostaglandin E₂), 176–177
- Phagocytic cells, 149–150
 - receptors for “bind-me” signals and bridging molecules, 157–159, 158f–159f
 - recruitment by “find-me” signals, 150–151
 - SIRP α receptor, 154, 154f
- Phagocytosis
 - apoptotic body removed by, 2
 - “bind-me” signals, 151, 153
 - “don’t-eat-me” signals and, 153–155
 - “eat-me” signals, 160, 162, 163f–165f
 - engulfment promotion of cell death, 162, 164, 166
 - engulfment-promoted cell death, 162, 164, 166
 - LC3-associated (LAP), 170–173, 172f–173f, 175, 175f
 - “tether-and-tickle” model, 156–157
- Phagolysosome, 165f, 166
- Phagophore, 139, 141, 142f
- Phagosome, 162, 165f, 166, 171, 172f–173f
- Pharmacological approaches to making cells die, 225–228
- Phosphatase and tensin homolog (PTEN), 208
- Phosphatidylserine, 22–23, 23f, 166
 - as “bind-me” signal, 151, 153
 - bridging molecules binding to, 155, 156f
 - detection of, 152–153, 152f–153f
 - externalization of, 160
 - phagocyte receptors for, 157–158, 158f
- Phosphoinositide 3-kinase (PI3K), 139
- Phospholipase A₂, 150, 151f, 176, 212
- Phospholipid derivative lysophosphatidylcholine (LPC), 150
- PIDD, 117–120, 117f, 205–206, 206f
- PIDDosome, 117, 117f
- Pin-1, 205, 205f
- PINK1, 144, 144f, 146
- Plasma membrane events caused by caspases, 21–22, 22f–23f
- Pleiotropy, antagonistic, 196, 196f
- Poly(ADP-ribose) polymerase 1 (PARP1), 132–133
- Potassium
 - in ischemia-reperfusion injury, 134
 - NLRP3 inflammasome and, 111
- Poxviruses, inhibitors of caspases, 43
- PPAR γ (peroxisome proliferator-activated receptor γ), 166, 167f, 168, 168f, 174
- Procaspases, 13
- Pro-death signal strength
 - expected relationship to cell death per unit time, 219
 - observable relationship to cell death per unit time, 220
- Prodomain, of caspases, 13, 14f
- Programmed cell death, 1–2, 179
- Proliferation
 - apoptosis and, 195–198
 - compensatory, 176–177, 176f
 - homeostatic, 177
- Prostaglandin E₂ (PGE₂), 176–177, 212–213
- Proteases, 5. *See also* Caspase(s)
 - BID as sensor of, 75
 - serine, 30
 - thiol, 11
- Protein-S, 155, 156f
- PRRs. *See* pattern-recognition receptors
- Pseudogout, 110, 114
- Pseudokinase, 125, 126f
- PTEN (phosphatase and tensin homolog), 208
- PTP (permeability transition pore), 55–56, 56f, 135

- PUMA, 68, 203, 205, 205f, 208
P2X purinoceptor 7 (P₂X₇), 111
PyD domain
 of AIM2, 113
 of ASC, 106, 107f, 109, 113
 of NLRP3, 109
Pyrin domain, 91f
Pyroptosis, 8, 37, 38f, 103, 108, 114
- R**
- RAC1, 162, 165f
RAGE (receptor for advanced glycation end products), 167
RAIDD, 117–119, 117f
Reactive oxygen species (ROS), 55, 133, 136–137, 144, 146, 170, 214
Reaper, 59, 60f, 182, 183f, 207, 224
Regulatory T cells (T_{reg}), 170
Removal of cells, 10
Reperfusion. See Ischemia-reperfusion injury
Retinal detachment, 132
Rheostat model, 66, 67f
RHOG, 162, 164f
Ribosomal protein imbalance, p53 induced by, 201
RING domain, 42
RIP-homology interaction motif (RHIM), 124, 125f
RIPK1, 96–97, 98, 98f, 123–124, 170, 216
 caspase-8 cleavage of, 127–128, 128f
 hypothetical connection between autophagy and necrosis, 146, 147f
 pharmacological inhibition by necrostatins, 228
 two faces of, 129–131, 130f
RIPK3, 124, 124f, 125f, 136
 activation, 129, 131
 cancer metastasis and, 214
 caspase-8-FLIP dimer cleavage of, 128
 development in deficient mice, 193
 hypothetical connection between autophagy and necrosis, 146, 147f
 inhibitors, 228–229
 MLKL activation by, 127
ROCK1 kinase, 22, 22f, 174–175
ROS. See Reactive oxygen species
Rotenone, 111
- S**
- Sabotage, 5
Scavenger receptors, 158, 159f
Scramblase, 23, 23f, 127, 152
Secondary necrosis, 122–123, 122f, 150
Selection in vertebrate development, 187–191
 lymphocytes, 188–191, 190f–191f
 negative selection, 189–191, 190f–191f
 neurons, 187–188, 188f
Self-nonsel discrimination in the immune system, 187, 188–191, 190f–191f
Serine protease, 30
Serpins, 43
Shigella flexneri, 114
Short hairpin (shRNA), 202
Sickle, 59, 60f, 207
SIRP α , 154, 154f
Skin, cornification process in, 4
SLE (systemic lupus erythematosus), 173–174, 174f
Sloughing of dead cells, 149
Smac, 51–52, 52f, 59, 60f, 99, 227
Smac-mimetic drugs, 227
SOCS1 (suppressor of cytokine signaling 1), 168, 168f
SP-A, 156, 156f
SP-D, 156, 156f
Sphingosine-1-phosphate, 150
Stabilin-2, 157, 158f, 162
“Stay-away” signal, 155
Step function, 219
Stress, 1, 8
Stress sensors, BH3-only proteins as, 74–79
 BID as protease sensor, 75
 BIM and BAD as growth factor signaling sensors, 75–76, 76g–77g
 BIM and BMF as anoikis mediators, 78
Strica, 36
Suicide, 1–2, 5, 46, 123
Suicide switches, 224–225
Superoxides, 24
Suppressor of cytokine signaling 1 (SOCS1), 168, 168f
Survival mechanism, autophagy as, 138–139
System Xc⁻, 204, 215, 227
Systemic lupus erythematosus (SLE), 173–174, 174f
- T**
- Tail-spike cell, death of, 181–182, 182f
T-cell receptors, 189
T-cell responses to tumors, 215–216
TCTP (translationally controlled tumor protein), 200

- “Tether and tickle” model, 156–157
TGF- β (transforming growth factor beta), 168, 168f, 170, 172f, 185
Thiol proteases, 11
Thrombospondin-1, 155, 156f
Thyroid hormone, 186
TIM4, 157–158, 158f
Tingible body macrophages, 155, 155f
TIR-domain-containing adapter-inducing interferon (TRIF), 124, 125f
TLRs (Toll-like receptors), 107, 166–167, 168f
TMEM16F, 23, 154
TNF. See Tumor necrosis factor
TNFR. See Tumor necrosis factor receptor
TNF-receptor-associated factor-2 (TRAF-2), 96
Toll-like receptors (TLRs), 107, 166–167, 168f
TORC1, 140, 142
TORC2, 140
Toxins, bacterial, 83–84, 84f, 112
TRA1, 181, 181f
TRADD (tumor necrosis factor receptor type 1-associated death domain), 96, 98, 98f, 100f
TRAF-2 (TNF-receptor-associated factor-2), 96
TRAIL (TNF-related apoptosis-inducing ligand), 90, 90f, 97–99, 203–204
 apoptosis and, 95–96
 receptors, 89, 90f
Transcription, bistability at level of, 223–224
Transferrin, 137, 138f
Transforming growth factor beta (TGF- β) family, 168, 168f, 170, 172f, 185
Translationally controlled tumor protein (TCTP), 200
Transthyretin-like protein 52 (TTR-52), 159, 161f
TRIF (TIR-domain-containing adapter-inducing interferon), 124, 125f
TRIO, 162, 164f
TSC1/2, 142
Tumor necrosis factor (TNF)
 as death ligand, 89, 90f, 96, 98f
 necrosis induced by, 123–124
 signaling for NF- κ B, antiapoptosis, and inflammation, 97f
 structure, 91f
Tumor necrosis factor (TNF) family
 death ligands, 89–91, 90f–91f
 death receptors, 89–91, 90f–91f
Tumor necrosis factor receptor (TNFR), 89, 90f, 91f, 128
 apoptotic signaling by, 96–99
 necroptosis caused by, 123–124, 124f
Tumor-suppressor proteins, 198–199, 208.
 See also p53
Type I cell death. See Apoptosis
Type II cell death. See Autophagic cell death
Type III cell death. See Necroptosis; Necrosis
Tyrosine phosphatases, 154
- U**
ULK1, 139–140, 141f, 171
Unfolded proteins, 214
Uric acid, 110, 110f, 150, 167
UVRAG, 143
- V**
Vacuoles, in autophagic cell death, 3
Venetoclax, 226
Vertebrate development, cell death in, 184–187, 185f–186f
Viral BCL-2 proteins, 82–83, 82f–83f
Viruses
 apoptosis induced by cytotoxic lymphocytes, 29–30, 29f
 caspase inhibitors, 39–43
 necroptosis as defense against, 132
Voltage-dependent anion channel (VDAC), 55, 56f
VPS34, 139–140, 141f, 143, 171
- W**
Waste management, 149–152, 166, 167f
WD domain, 48, 49f, 56–58, 57f
West Nile virus, 132
WIPI2, 140–141
Wound healing, 176
- X**
Xc⁻, 204, 215, 227
XIAP, 41–43, 43f, 51–52, 52f, 99–100, 227
Xjr8, 151
- Z**
Z-DNA-binding protein 1 (ZBP1), 124, 125f